Ablynx Regains Rights on Drugs Licensed to Pfizer, Sets Terms

Ablynx NV (ABLX) said it regained the rights on its experimental TNF-alpha blocking medicines that were licensed to Pfizer Inc. (PFE) and agreed to pay Pfizer milestones of as much as $50 million following an eventual third-party alliance for the drugs as well as royalties on sales.

To contact the editor responsible for this story: John Martens at jmartens1@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.